Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

Literature DB >> 7473820

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

F L Meyskens¹, K J Kopecky, C W Taylor, R D Noyes, R J Tuthill, E M Hersh, L G Feun, J H Doroshow, L E Flaherty, V K Sondak.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1995 PMID： 7473820 DOI： 10.1093/jnci/87.22.1710

Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506

Keyword Cloud
Cited

× No keyword cloud information.

30 in total

Review 1. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors: Xue Bai; David E Fisher; Keith T Flaherty
Journal: Nat Rev Clin Oncol Date: 2019-09 Impact factor: 66.675

Review 2. Shedding light on melanocyte pathobiology in vivo.

Authors: M Raza Zaidi; Edward C De Fabo; Frances P Noonan; Glenn Merlino
Journal: Cancer Res Date: 2012-03-15 Impact factor: 12.701

Review 3. The two faces of interferon-γ in cancer.

Authors: M Raza Zaidi; Glenn Merlino
Journal: Clin Cancer Res Date: 2011-06-24 Impact factor: 12.531

4. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Authors: Karl-Johan Malmberg; Victor Levitsky; Håkan Norell; Cristina Teixeira de Matos; Mattias Carlsten; Kjell Schedvins; Hodjattallah Rabbani; Alessandro Moretta; Kalle Söderström; Jelena Levitskaya; Rolf Kiessling
Journal: J Clin Invest Date: 2002-11 Impact factor: 14.808

5. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.

Authors: Xiaohui Zhang; Yuanyuan Zeng; Qiuxia Qu; Jianjie Zhu; Zeyi Liu; Weiwei Ning; Hui Zeng; Nan Zhang; Wenwen Du; Cheng Chen; Jian-An Huang
Journal: Int J Clin Oncol Date: 2017-07-26 Impact factor: 3.402

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

Review 1. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Review 2. Shedding light on melanocyte pathobiology in vivo.

Review 3. The two faces of interferon-γ in cancer.

4. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

5. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.

Review 6. Recent advances in the care of the patient with malignant melanoma.

7. Anal melanoma.

8. "First do no harm" and the importance of prediction in oncology.

Review 9. Current treatment options for malignant melanoma.

10. Comparison of survival outcomes among cancer patients treated in and out of clinical trials.